PMID- 19941413
OWN - NLM
STAT- MEDLINE
DCOM- 20100309
LR  - 20100122
IS  - 1365-2060 (Electronic)
IS  - 0785-3890 (Linking)
VI  - 42
IP  - 1
DP  - 2010
TI  - Telomere length and outcome in heart failure.
PG  - 36-44
LID - 10.3109/07853890903321567 [doi]
AB  - BACKGROUND: Telomeres are causally involved in senescence. Senescence is a 
      potential factor in the pathogenesis and progression of heart failure. In heart 
      failure telomeres are shorter, but the prognostic value associated with telomere 
      length has not been defined. METHODS: Telomere length was prospectively 
      determined by quantitative polymerase chain reaction in 890 patients with New 
      York Heart Association (NYHA) functional class II to IV heart failure. After 18 
      months, we examined the association between telomere length and the predefined 
      primary end-point: time to death or hospitalization for heart failure. RESULTS: 
      Mean age of the patients was 71 years, 39% were women, 51% were in NYHA class II, 
      and 49% were in class III/IV. A total of 344 patients reached the primary 
      end-point (130 deaths and 214 hospitalizations). Patients with shorter telomeres 
      were at an increased risk of reaching the primary end-point (hazard ratio 1.79; 
      95% confidence interval (CI) 1.21-2.63). In multivariate analysis shorter 
      telomere length remained associated with a higher risk for death or 
      hospitalization (hazard ratio, 1.74; 95% CI 1.07-2.95) after adjustment for age 
      of heart failure onset, gender, hemoglobin, renal function, and N-terminal 
      pro-B-type natriuretic peptide level, a history of stroke, atrial fibrillation, 
      and diabetes. CONCLUSIONS: Shorter length of telomeres predicts the occurrence of 
      death or hospitalization in patients with chronic heart failure.
FAU - van der Harst, Pim
AU  - van der Harst P
AD  - Department of Cardiology, University Medical Center Groningen, University of 
      Groningen, Hanzeplein 1, 9700 RB Groningen, The Netherlands. 
      p.van.der.harst@thorax.umcg.nl
FAU - de Boer, Rudolf A
AU  - de Boer RA
FAU - Samani, Nilesh J
AU  - Samani NJ
FAU - Wong, Liza S M
AU  - Wong LS
FAU - Huzen, Jardi
AU  - Huzen J
FAU - Codd, Veryan
AU  - Codd V
FAU - Hillege, Hans L
AU  - Hillege HL
FAU - Voors, Adriaan A
AU  - Voors AA
FAU - van Gilst, Wiek H
AU  - van Gilst WH
FAU - Jaarsma, Tiny
AU  - Jaarsma T
FAU - van Veldhuisen, Dirk J
AU  - van Veldhuisen DJ
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Ann Med
JT  - Annals of medicine
JID - 8906388
RN  - 114471-18-0 (Natriuretic Peptide, Brain)
SB  - IM
MH  - Aged
MH  - Aged, 80 and over
MH  - Atrial Fibrillation/complications/metabolism
MH  - Diabetes Complications/metabolism
MH  - Female
MH  - Heart Failure/*mortality/*physiopathology
MH  - Humans
MH  - Male
MH  - Natriuretic Peptide, Brain/metabolism
MH  - Prognosis
MH  - Stroke/complications/metabolism
MH  - Telomere/genetics/*metabolism
EDAT- 2009/11/28 06:00
MHDA- 2010/03/10 06:00
CRDT- 2009/11/28 06:00
PHST- 2009/11/28 06:00 [entrez]
PHST- 2009/11/28 06:00 [pubmed]
PHST- 2010/03/10 06:00 [medline]
AID - 10.3109/07853890903321567 [doi]
PST - ppublish
SO  - Ann Med. 2010;42(1):36-44. doi: 10.3109/07853890903321567.